https://www.octapharma.com/news/our-employees/2025/iecp-a-unique-opportunity-for-personal-growth-and-career-development https://www.octapharma.com/news/our-employees/2025/-we-re-a-team-yet-also-a-community-you-re-not-just-a-number-here https://www.octapharma.com/news/our-employees/2025/turning-a-simple-idea-into-a-global-platform https://www.octapharma.com/news/press-release/2024/octapharma-usa-receives-fda-emergency-use-authorization-for-octaplaslg-powder https://www.octapharma.com/news/our-employees/2025/careers-in-motion-what-happens-when-you-say-yes-to-moving-somewhere-new- https://www.octapharma.com/news/press-release/2024/jama-publishes-study-on-balfaxar-efficacy-for-warfarin-reversal-in-surgery https://www.octapharma.com/news/innovation-and-science/2024/improving-care-for-af-patients-managing-factor-xa-inhibitor-bleeding-risks-in-urgent-surgery https://www.octapharma.com/news/our-employees/2025/-octapharma-is-the-most-exciting-company-i-ve-worked-for https://www.octapharma.com/news/press-release/2024/fda-approves-fibryga-for-acquired-fibrinogen-deficiency https://www.octapharma.com/news/our-employees/2025/mentorsip-at-octapharma-investing-in-the-future https://www.octapharma.com/news/press-release/2024/octapharma-at-esaic-2024 https://www.octapharma.com/news/press-release/2024/octapharma-at-isth-2024 https://www.octapharma.com/news/our-employees/2025/it-s-not-just-about-the-business-it-s-about-improving-lives https://www.octapharma.com/news/press-release/2024/octapharma-at-the-forefront-of-rare-bleeding-disorders-at-the-wfh-2024-world-congress https://www.octapharma.com/news/our-employees/2025/at-octapharma-communication-is-the-most-important-thing https://www.octapharma.com/news/corporate-news/2024/the-aland-island-meeting-on-von-willebrand-disease https://www.octapharma.com/news/press-release/2024/octapharma-makes-a-strong-impression-at-the-2024-aan-annual-meeting-in-denver https://www.octapharma.com/news/corporate-news/2024/octapharma-dessau-shines-as-a-regional-finalist-in-the-prestigious-grosser-preis-des-mittelstands https://www.octapharma.com/news/press-release/2024/octapharma-usa-fda-grants-orphan-drug-exclusivity-to-wilate-the-first-vwf-concentrate-for-prophylaxis-in-all-types-of-vwd https://www.octapharma.com/octapharma https://www.octapharma.com/news/press-release/2025/octapharma-presents-new-clinical-data-investigating-frontiers-of-treatment-for-autoimmune-disorders-at-american-academy-of-neurology-conference https://www.octapharma.com/news/corporate-news/2024/raising-awareness-of-myositis https://www.octapharma.com/news/press-release/2024/expanded-website-will-raise-awareness-of-von-willebrand-disease https://www.octapharma.com/news/our-employees/2020/creating-a-positive-impact-is-what-octapharma-is-all-about https://www.octapharma.com/news/corporate-news/2025/octapharma-vienna-recognised-among-austria-s-leading-companies https://www.octapharma.com/news/press-release/2025/Octapharma-announces-superior-haemostatic-efficacy-of-4f-pcc-over-frozen-plasma-in-cardiac-surgical-bleeding https://www.octapharma.com/news/corporate-news/2024/indonesian-doctors-gain-unique-insights-at-octapharma-springe https://www.octapharma.com/news/press-release/2024/octapharma-to-present-clinical-and-scientific-data-at-EAHAD-2024 https://www.octapharma.com/news/our-employees/2020/world-blood-donor-day-celebrating-every-donation https://www.octapharma.com/news/corporate-news/2025/octapharma-dessau-gmbh-receives-the-grand-prize-for-medium-sized-enterprises-2025 https://www.octapharma.com/news/press-release/2025/nhs-patients-receive-medicines-manufactured-by-octapharma-using-uk-donated-plasma-for-the-first-time-in-almost-30-years https://www.octapharma.com/news/corporate-news/2024/two-decades-of-pioneering-patient-centred-care https://www.octapharma.com/news/press-release/2024/octapharma-announces-availability-of-balfaxar-for-warfarin-reversal-in-urgent-surgery-invasive-procedures https://www.octapharma.com/news/our-employees/2020/entrepreneurship https://www.octapharma.com/news https://www.octapharma.com/news/patient-stories/2025/patient-s-visit-to-springe-reminds-us-all-why-we-make-products-that-matter https://www.octapharma.com/news/corporate-news/2025/simplifying-igg-therapy-with-flexig https://www.octapharma.com/news/press-release/2025/octapharma-expands-production-for-the-global-market-at-its-manufacturing-site-in-vienna https://www.octapharma.com/news/press-release/2024/publication-of-data-from-wil-31-study https://www.octapharma.com/news/our-employees/2020/sustainability https://www.octapharma.com/news/patient-stories/2025/world-haemophilia-day-2025 https://www.octapharma.com/news/corporate-news/2025/our-approach-to-sustainability https://www.octapharma.com/news/press-release/2023/octapharma-usa-fda-grants-expanded-approval-to-wilate-as-the-first-vwf-concentrate-for-prophylaxis-in-all-types-of-vwd https://www.octapharma.com/news/press-release/2020/positive-results-from-proderm-study-of-octagam-10 https://www.octapharma.com/news/our-employees/2020/leadership https://www.octapharma.com/news/donor-stories/sisters-in-service https://www.octapharma.com/news/corporate-news/2025/octapharma-appointed-sole-fractionator-for-uk-s-plasma-programme https://www.octapharma.com/news/corporate-news/2024/news-update https://www.octapharma.com/news/press-release/2023/octapharma-to-present-new-clinical-and-scientific-data-at-ash-2023 https://www.octapharma.com/news/our-employees/2021/it-all-starts-at-octapharma-ab-logistics-centre-in-arlandastad https://www.octapharma.com/news/press-release/2020/fda-approval-of-updated-nuwiq-to-include-immunogenicity-data-in-pups https://www.octapharma.com/news/our-employees/2020/integrity https://www.octapharma.com/news/donor-stories/dancing-against-the-odds https://www.octapharma.com/news/patient-stories/2025/a-journey-of-patience-and-resilience https://www.octapharma.com/news/corporate-news/2024/celebrating-international-women-s-day https://www.octapharma.com/news/press-release/2023/new-nuwiq-study-published-in-the-european-journal-of-haematology https://www.octapharma.com/news/corporate-news/2023/raising-awareness-of-immune-thrombocytopenic-purpura https://www.octapharma.com/news/press-release/2021/octagam-10-receives-7-years-of-market-exclusivity-for-adult-dermatomyositis https://www.octapharma.com/news/press-release/2020/patient-recruitment-starts-for-the-international-pro-sid-study https://www.octapharma.com/news/our-employees/2020/ownership https://www.octapharma.com/italy https://www.octapharma.com/news/donor-stories/be-a-hero-time-and-time-again https://www.octapharma.com/news/corporate-news/2025/setting-new-standards-in-patient-bleeding-management https://www.octapharma.com/news/press-release/2023/octapharma-to-be-honored-for-myositis-research-at-tma-annual-patient-conference https://www.octapharma.com/news/corporate-news/2023/celebrating-international-women-s-day https://www.octapharma.com/news/our-employees/2022/building-on-strong-values https://www.octapharma.com/news/press-release/2021/fda-approves-octagam-10percent-for-adult-dermatomyositis https://www.octapharma.com/news/our-employees/2021/culture-drives-performance https://www.octapharma.com/news/press-release/2020/octapharma-usa-announces-medicare-part-b-approval-of-cutaquig-16-5-for-adult-pi-patients https://www.octapharma.com/news/our-employees/2020/our-values https://www.octapharma.com/about-us/engagement/international-events https://www.octapharma.com/news/corporate-news/2024/financial-review-2023 https://www.octapharma.com/news/donor-stories/loyalty-and-community https://www.octapharma.com/news/press-release/2023/octapharma-s-prothrombin-complex-concentrate-balfaxar-receives-fda-approval-for-warfarin-reversal-in-urgent-surgery-invasive-procedures https://www.octapharma.com/news/corporate-news/2023/rare-disease-day-a-look-at-dermatomyositis https://www.octapharma.com/news/press-release/2021/isth-2021-new-clinical-and-scientific-findings-encompassing-the-haematology-portfolio https://www.octapharma.com/news/press-release/2020/octapharma-launches-phase-3-superiority-study-for-pediatric-acute-onset-neuropsychiatric-syndrome https://www.octapharma.com/news/corporate-news/2020/new-igcares-app-helps-patients-safely-manage-pi https://www.octapharma.com/news/our-employees/2020/reaching-new-donors https://www.octapharma.com/career https://www.octapharma.com/news/donor-stories/from-survivor-to-advocate https://www.octapharma.com/news/corporate-news/2024/building-on-our-successes https://www.octapharma.com/news/press-release/2023/octapharma-presents-new-data-at-isth-2023 https://www.octapharma.com/news/corporate-news/2023/octapharma-group-delivers-strong-growth-in-sales-and-operating-income-in-2022 https://www.octapharma.com/news/press-release/2022/octapharma-to-present-new-clinical-data-and-studies-at-ash-2022 https://www.octapharma.com/news/press-release/2021/approval-of-octagam-10percent-for-adults-with-dermatomyositis https://www.octapharma.com/news/press-release/2020/fibryga-receives-health-canada-approval-to-treat-acquired-fibrinogen-deficiency-in-surgical-settings https://www.octapharma.com/news/corporate-news/2020/octapharma-italy-launches-wicare-home-care-for-patients-with-von-willebrand-disease https://www.octapharma.com/news/our-employees/2020/petra-loefgren-shift-manager https://www.octapharma.com/news/our-employees/2025/working-at-octapharma-is-like-cheering-for-a-winning-team https://www.octapharma.com/news/corporate-news/celebrating-women-in-science-on-international-women-s-day https://www.octapharma.com/news/corporate-news/2025/we-are-all-part-of-a-vital-chain https://www.octapharma.com/news/donor-stories/just-an-ordinary-lifesaver https://www.octapharma.com/news/press-release/2023/octapharma-at-european-hematology-association-congress-2023 https://www.octapharma.com/news/corporate-news/2023/delivering-strong-performance-in-2022 https://www.octapharma.com/news/press-release/2022/proderm-study-results-of-octagam-10-treatment-in-patients-with-dermatomyositis-published-in-the-new-england-journal-of-medicine https://www.octapharma.com/news/corporate-news/2022/octapharma-dessau-housing-for-ukrainian-refugees https://www.octapharma.com/news/press-release/2021/study-suggests-that-4f-pcc-can-be-used-as-a-substitute-for-frozen-plasma https://www.octapharma.com/news/corporate-news/2021/donating-plasma-and-saving-lives https://www.octapharma.com/news/press-release/2020/octapharma-reports-positive-data-from-octagam-usage-in-critically-ill-covid-19-patients https://www.octapharma.com/news/corporate-news/2020/octapharma-supports-new-covid-19-study-in-us https://www.octapharma.com/news/our-employees/2020/alma-torokoff-process-technician https://www.octapharma.com/about-us/who-we-are https://www.octapharma.com/about-us https://www.octapharma.com/news/corporate-news/2019/celebrating-our-milestones https://www.octapharma.com/ https://www.octapharma.com/news/press-release/2019/octapharma-demonstrates-commitment-to-improving-haemophilia-a-treatment-at-eahad https://www.octapharma.com/news/corporate-news/2026/financial-review-2025 https://www.octapharma.com/sustainability https://www.octapharma.com/news/our-employees/2025/my-work-at-octapharma-simply-fulfills-me https://www.octapharma.com/news/innovation-and-science/2025/small-antibodies-with-big-implications https://www.octapharma.com/news/press-release/2023/journal-of-clinical-immunology-publishes-octapharma-usa-research-on-cutaquig https://www.octapharma.com/news/corporate-news/2023/it-started-with-a-belief https://www.octapharma.com/news/donor-stories/my-son-is-a-warrior https://www.octapharma.com/news/press-release/2022/isth-2022 https://www.octapharma.com/octapharma/social-media-community-guidelines https://www.octapharma.com/news/corporate-news/2022/the-essential-role-of-pbm-during-the-pandemic https://www.octapharma.com/news/corporate-news/2022/securing-our-future-by-boosting-capacity https://www.octapharma.com/news/corporate-news/2022/earning-donors-trust https://www.octapharma.com/news/press-release/2021/fda-approvals-strengthen-octapharma-usa-pediatric-critical-care-product-portfolio https://www.octapharma.com/news/corporate-news/2021/ensuring-plasma-supplies-during-covid-19 https://www.octapharma.com/news/press-release/2020/isth2020-results https://www.octapharma.com/news/innovation-and-science/2020/patient-blood-management https://www.octapharma.com/news/corporate-news/2020/octapharma-takes-action-on-covid-19 https://www.octapharma.com/news/our-employees/2020/david-lindskog-laboratory-engineer https://www.octapharma.com/career/vacancies https://www.octapharma.com/news/press-release/2019/positive-results-for-fibryga-published-in-the-journal-of-thrombosis-and-haemostasis https://www.octapharma.com/news/our-employees/2018/from-childhood-dream-to-research-team https://www.octapharma.com/news/corporate-news/2019/update-of-summary-of-product-characteristics-for-nuwiq https://www.octapharma.com/about-us/engagement/international-events/2026/gcom-2026 https://www.octapharma.com/news/corporate-news/2026/octapharma-shareholders-look-back-on-2025-performance https://www.octapharma.com/sustainability/social-responsibility https://www.octapharma.com/news/patient-stories/2025/i-m-proud-of-who-i-ve-become https://www.octapharma.com/news/our-employees/2024/stepping-up-making-the-most-of-opportunities-at-octapharma https://www.octapharma.com/news/corporate-news/2024/ops-tansforming-production-to-meet-rising-demand https://www.octapharma.com/career/international-early-career-program https://www.octapharma.com/news/patient-stories/2023/access-for-all-world-haemophilia-day-2023 https://www.octapharma.com/news/press-release/2023/octapharma-usa-grant-supports-pans-pandas-education-event-at-nhia-conference https://www.octapharma.com/news/corporate-news/2023/driving-sustainability-at-octapharma https://www.octapharma.com/news/donor-stories/without-plasma-i-would-not-be-alive-today https://www.octapharma.com/news/press-release/2022/octapharma-to-address-unmet-needs-in-VWD-at-wfh-2022 https://www.octapharma.com/news/press-release/2021/final-data-from-the-nuprotect-study-published-on-the-immunogenicity-of-nuwiq-in-previously-untreated-patients-with-severe-haemophilia-a https://www.octapharma.com/news/corporate-news/2021/committed-to-the-fight-against-covid-19 https://www.octapharma.com/news/press-release/2020/octapharma-usa-extends-funding-for-covid-19-study https://www.octapharma.com/news/our-employees/2020/ake-andersson-electrical-automation-engineer https://www.octapharma.com/news/press-release/2019/final-results-from-the-nuprotect-study-demonstrating-efficacy-of-nuwiq https://www.octapharma.com/news/our-employees/2018/persistence-and-ingenuity-pays-off https://www.octapharma.com/news/corporate-news/2019/octapharma-group-reports-strong-results-for-2018 https://www.octapharma.com/news/innovation-and-science/2018/timely-help-for-critically-ill-patients https://www.octapharma.com/news/corporate-news/2018/octapharma-group-publishes-2017-annual-results https://www.octapharma.com/about-us/engagement/international-events/2026/isicem-2026 https://www.octapharma.com/news/corporate-news/2026/strengthening-our-climate-ambitions-octapharma-s-path-to-net-zero https://www.octapharma.com/news/innovation-and-science/2026/our-production-sites-record-measurable-impacts-under-ops-2-0 https://www.octapharma.com/news/our-employees/2025/at-octapharma-i-have-the-feeling-that-im-important https://www.octapharma.com/about-us/who-we-are/annual-report/annual-report-2023 https://www.octapharma.com/news/our-employees/2024/maria-s-path-to-leadership-a-story-of-growth-and-development-at-octapharma https://www.octapharma.com/flexig https://www.octapharma.com/news/press-release/2023/octapharma-usa-requests-fda-approval-for-wilate-vwd-prophylaxis-supplement https://www.octapharma.com/news/corporate-news/2023/resonating-with-our-donors https://www.octapharma.com/news/patient-stories/2023/to-transfuse-or-not-to-transfuse-a-challenging-question-in-pre-hospital-critical-care https://www.octapharma.com/news/donor-stories/i-donate-twice-a-week https://www.octapharma.com/news/press-release/2022/octapharma-group-delivers-strong-growth-in-sales-and-operating-income-in-2021 https://www.octapharma.com/news/corporate-news/2022/letter-from-our-chairman-annual-report-2021 https://www.octapharma.com/news/press-release/2021/new-consensus-recommendations-on-treatment-of-secondary-antibody-deficiency https://www.octapharma.com/news/corporate-news/2021/letter-from-our-chairman-annual-report-2020 https://www.octapharma.com/latam https://www.octapharma.com/news/patient-stories/2020/take-one-day-at-a-time-and-live https://www.octapharma.com/news/press-release/2020/fda-approves-octapharma-usa-investigational-new-drug-application https://www.octapharma.com/news/corporate-news/2020/message-from-our-ceo https://www.octapharma.com/news/corporate-news/2017/octapharma-group-publishes-2016-annual-results https://www.octapharma.com/about-us/engagement/patient-engagements https://www.octapharma.com/news/press-release/2019/final-results-from-the-nuprotect-study https://www.octapharma.com/news/our-employees/2018/medicine-as-an-art-form https://www.octapharma.com/news/corporate-news/2018/octapharma-share-promising-preclinical-data-for-subq-8 https://www.octapharma.com/news/corporate-news/2019/new-data-on-haemophilia-a-or-von-willebrand-disease-at-isth-2019 https://www.octapharma.com/news/innovation-and-science/2018/low-inhibitor-rate-with-octanate-in-previously-untreated-patients https://www.octapharma.com/news/innovation-and-science/2020/trust-swift-decision-making-and-excellent-medical-skills-are-a-priority-for-intensive-care https://www.octapharma.com/news/our-employees/2026/international-women-s-day-three-colleagues-touching-countless-lives https://www.octapharma.com/news/corporate-news/2026/when-people-feel-seen-a-new-kind-of-workplace https://www.octapharma.com/news/innovation-and-science/2026/turning-data-into-discovery https://www.octapharma.com/news/patient-stories/2026/learning-the-strength-of-vulnerability-one-step-at-a-time https://www.octapharma.com/latam/almas https://www.octapharma.com/sustainability/environmental-stewardship-and-resilience https://www.octapharma.com/news/our-employees/2025/trust-is-important-its-an-essential-value https://www.octapharma.com/news/innovation-and-science/2025/how-big-data-is-changing-the-game-at-octapharma https://www.octapharma.com/news/our-employees/2024/investing-in-growth-octapharma-s-dedication-to-employee-development-and-career-advancement https://www.octapharma.com/news/innovation-and-science/2024/wil-31-expanding-treatment-options-for-vwd https://www.octapharma.com/news/corporate-news/2024/building-the-organisation-of-tomorrow https://www.octapharma.com/news/patient-stories/2024/a-recipe-for-a-good-life https://www.octapharma.com/news/innovation-and-science/2023/driven-by-curiosity https://www.octapharma.com/news/patient-stories/2023/living-with-the-mystery-of-dermatomyositis https://www.octapharma.com/news/corporate-news/2023/letter-from-our-ceo-annual-report-2022 https://www.octapharma.com/news/press-release/2023/european-authorities-approve-octaplaslg-for-pre-hospital-transfusion https://www.octapharma.com/products/industrial-collaboration https://www.octapharma.com/news/donor-stories/a-mother-s-tireless-fight-for-her-daughter-s-health https://www.octapharma.com/news/patient-stories/2022/you-can-t-stop-him-now https://www.octapharma.com/news/corporate-news/2022/financial-review-2021 https://www.octapharma.com/news/press-release/2022/spotlight-on-the-challenges-of-managing-inhibitors-in-haemophilia-eahad-2022 https://www.octapharma.com/news/patient-stories/2021/adapting-to-change-whd-2021 https://www.octapharma.com/news/corporate-news/2021/financial-review-2020 https://www.octapharma.com/news/press-release/2021/akron-biotech-signs-exclusive-global-agreement-with-octapharma https://www.octapharma.com/news/patient-stories/2020/winners-never-quit https://www.octapharma.com/news/press-release/2020/final-results-from-the-procid-study https://www.octapharma.com/news/corporate-news/2017/octapharma-activities-prominent-at-the-upcoming-2017-isth-congress https://www.octapharma.com/news/our-employees/2020/adam-llarena-single-donation-controller https://www.octapharma.com/news/innovation-and-science/2018/octapharma-present-new-data-on-the-benefits-of-nuwiq https://www.octapharma.com/news/innovation-and-science/2020/the-story-of-octapharmas-high-purity-human-fibrinogen-concentrate https://www.octapharma.com/news/corporate-news/2020/continuing-to-invest-in-the-future-prosperity-of-octapharma https://www.octapharma.com/news/our-employees/2018/using-big-data-to-improve-lives https://www.octapharma.com/news/corporate-news/2019/update-on-the-development-of-subq-8-isth-2019 https://www.octapharma.com/news/corporate-news/2018/octapharma-to-build-new-multi-use-venue https://www.octapharma.com/news/press-release/2019/fibryga-receives-european-label-extension-to-treat-acquired-fibrinogen-deficiency-afd https://www.octapharma.com/news/our-employees/2026/iecp-moments-two-journeys-one-way-of-learning https://www.octapharma.com/news/press-release/2026/octapharma-strengthens-its-innovation-strategy-with-a-usd-11-75-million-series-a-investment-in-abram-scientific https://www.octapharma.com/news/corporate-news/2026/built-to-belong-how-octapharma-plasma-inc-made-culture-its-strongest-competitive-advantage https://www.octapharma.com/news/innovation-and-science/2026/an-overlooked-risk-in-heart-surgery https://www.octapharma.com/news/patient-stories/2026/choosing-adventure-choosing-life https://www.octapharma.com/about-us/engagement/international-events/2026/eahad-2026 https://www.octapharma.com/news/press-release/2025/octapharma-releases-results-phase3-superiority-study-pediatric-acuteonset-neuropsychiatric-syndrome https://www.octapharma.com/news/corporate-news/2025/financial-review-2024 https://www.octapharma.com/news/our-employees/2024/advancing-talent-at-octapharma https://www.octapharma.com/news/innovation-and-science/2024/enabling-innovation-in-bleeding-management-and-critical-care https://www.octapharma.com/news/patient-stories/2024/access-for-everyone-learning-to-live-with-haemophilia https://www.octapharma.com/news/corporate-news/2024/raising-awareness-of-kawasaki-disease https://www.octapharma.com/news/innovation-and-science/2023/a-culture-of-entrepreneurship https://www.octapharma.com/news/patient-stories/2023/building-a-dream-family-despite-vwd https://www.octapharma.com/news/corporate-news/2023/octapharma-providing-humanitarian-assistance-in-tuerkiye https://www.octapharma.com/news/press-release/2023/octapharma-at-eahad-2023 https://www.octapharma.com/news/patient-stories/2022/successful-treatment-of-dermatomyositis https://www.octapharma.com/news/patient-stories/2022/pbm-and-use-of-factor-concentrates-separation-of-conjoined-twins https://www.octapharma.com/news/patient-stories/2022/living-with-von-willebrand-disease https://www.octapharma.com/news/patient-stories/2022/dermatomyositis-diagnosis https://www.octapharma.com/news/press-release/2022/indication-cutaquig-secondary-immunodeficiencies https://www.octapharma.com/news/patient-stories/2021/reaching-a-community-in-need-helping-patients-with-pans https://www.octapharma.com/news/patient-stories/2021/cancer-was-not-part-of-the-plan https://www.octapharma.com/news/patient-stories/2021/facing-vwd-during-covid-19-as-both-a-nurse-and-patient https://www.octapharma.com/news/press-release/2021/octapharma-to-demonstrate-ongoing-commitment-at-the-14th-eahad-annual-congress https://www.octapharma.com/news/patient-stories/2020/my-life-with-vwd-making-a-difference https://www.octapharma.com/news/corporate-news/2017/octapharma-symposium-at-isth-berlin https://www.octapharma.com/news/press-release/2020/octapharma-group-delivered-strong-growth-in-both-sales-and-operating-income-in-2019 https://www.octapharma.com/news/press-release/2019/octapharma-announces-publication-of-data-on-fibryga https://www.octapharma.com/news/our-employees/2018/an-eye-for-detail https://www.octapharma.com/news/our-employees/2020/we-are-octapharma https://www.octapharma.com/news/corporate-news/2020/continuing-the-impact-of-our-products-for-generations-to-come https://www.octapharma.com/news/corporate-news/2019/new-data-isth-2019 https://www.octapharma.com/plasma https://www.octapharma.com/news/innovation-and-science/2018/octapharma-announces-approval-of-new-nuwiq-product-strengths https://www.octapharma.com/news/innovation-and-science/2020/testing-boundaries https://www.octapharma.com/about-us/who-we-are/annual-report/annual-report-2021 https://www.octapharma.com/about-us/who-we-are/annual-report https://www.octapharma.com/news/corporate-news/2025/built-on-strength-and-resilience https://www.octapharma.com/news/innovation-and-science/2021/patient-blood-management-a-new-standard-of-care https://www.octapharma.com/news/our-employees/2017/bringing-new-optimal-therapies https://www.octapharma.com/news/our-employees/2018/getting-our-medicines-to-patients https://www.octapharma.com/news/innovation-and-science/2018/octapharma-receives-swissmedic-approval-for-fibryga https://www.octapharma.com/products https://www.octapharma.com/news/patient-stories/2020/always-on-the-go https://www.octapharma.com/news/innovation-and-science/2017/isth-2017-berlin-octapharma-presents-exciting-nuwiq-data https://www.octapharma.com/news/patient-stories/2016/blood-is-essential-for-the-wellbeing-of-everyone https://www.octapharma.com/about-us/diseases-and-therapies https://www.octapharma.com/about-us/engagement https://www.octapharma.com/products/product-overview https://www.octapharma.com/news/patient-stories/2018/real-hope-for-brandon https://www.octapharma.com/news/patient-stories/2017/octapharma-usa-sponsors-hope-ignites-stories-to-inspire https://www.octapharma.com/news/patient-stories/2018/engaging-with-patients https://www.octapharma.com/about-us/who-we-are/annual-report/annual-report-2024 https://www.octapharma.com/products/industrial-collaboration/immunoglobulin https://www.octapharma.com/values https://www.octapharma.com/news/patient-stories/2017/octapharma-usa-sponsors-nhf-annual-meeting https://www.octapharma.com/news/patient-stories/2018/strong-commitment-for-the-two-brothers-from-estonia https://www.octapharma.com/octapharma/pharmacovigilance-data-privacy-statement https://www.octapharma.com/news/patient-stories/2016/one-in-ten-patients https://www.octapharma.com/news/our-employees/2016/saving-lives https://www.octapharma.com/news/our-employees/2017/inspecting-finished-products https://www.octapharma.com/news/patient-stories/2020/why-worry- https://www.octapharma.com/about-us/diseases-and-therapies/haematology https://www.octapharma.com/news/innovation-and-science/2017/octapharma-underlines-strong-commitment-to-haemophilia-a-patients https://www.octapharma.com/products/product-overview/albunorm https://www.octapharma.com/about-us/who-we-are/leadership https://www.octapharma.com/news/innovation-and-science/2018/new-canadian-study-to-improve-eradication-of-inhibitors https://www.octapharma.com/about-us/who-we-are/annual-report/annual-report-2022 https://www.octapharma.com/products/industrial-collaboration/human-fibrinogen-concentrate https://www.octapharma.com/about-us/diseases-and-therapies/immunotherapy https://www.octapharma.com/news/innovation-and-science/2017/publication-of-clinical-data-demonstrating-low-immunogenicity-and-excellent-efficacy-of-nuwiq https://www.octapharma.com/products/product-overview/atenativ https://www.octapharma.com/news/patient-stories/2017/octapharma-usa-grant-supports-mission-of-first-hemophiliac-to-climb-the-seven-summits-of-the-world https://www.octapharma.com/news/our-employees/2017/preserving-human-proteins https://www.octapharma.com/news/patient-stories/2016/i-am-lucky-to-be-alive https://www.octapharma.com/products/industrial-collaboration/human-antithrombin-iii-concentrate https://www.octapharma.com/about-us/diseases-and-therapies/critical-care https://www.octapharma.com/products/production-process https://www.octapharma.com/news/patient-stories/2017/octapharma-donates-30-5-million-international-units-of-its-medicine https://www.octapharma.com/products/product-overview/cutaquig https://www.octapharma.com/news/patient-stories/2020/surviving-the-unknown https://www.octapharma.com/news/our-employees/2017/investing-to-increase-capacity-and-automation https://www.octapharma.com/about-us/who-we-are/milestones https://www.octapharma.com/octapharma/contact https://www.octapharma.com/news/patient-stories/2016/there-is-always-time-in-life-for-an-adventure https://www.octapharma.com/products/industrial-collaboration/virus-inactivated-plasma https://www.octapharma.com/news/patient-stories/2020/world-hemophilia-day-2020 https://www.octapharma.com/products/product-overview/fibryga https://www.octapharma.com/news/patient-stories/2017/donors-like-my-father https://www.octapharma.com/octapharma/privacy-statement https://www.octapharma.com/products/quality-and-safety https://www.octapharma.com/news/patient-stories/2016/it-is-as-if-a-big-hammer-falls-down-on-you https://www.octapharma.com/news/our-employees/2017/purifying-products https://www.octapharma.com/products/industrial-collaboration/human-serum-albumin https://www.octapharma.com/products/product-overview/gammanorm https://www.octapharma.com/octapharma/legal-statement https://www.octapharma.com/news/our-employees/2017/cultivating-factor-viii https://www.octapharma.com/news/patient-stories/2016/my-illness-has-given-me-the-will-to-live https://www.octapharma.com/news/patient-stories/2017/donating-plasma https://www.octapharma.com/products/industrial-collaboration/industrial-customers-contact https://www.octapharma.com/news/our-employees/2017/validating-cleaning-methods https://www.octapharma.com/news/patient-stories/2016/when-i-am-dancing-i-feel-free https://www.octapharma.com/products/product-overview/nuwiq https://www.octapharma.com/news/patient-stories/2016/a-hyperactive-kid-with-haemophilia-is-a-dangerous-cocktail https://www.octapharma.com/products/product-overview/octagam-5 https://www.octapharma.com/news/our-employees/2017/getting-the-right-material https://www.octapharma.com/products/product-overview/octanate https://www.octapharma.com/about-us/research-and-development https://www.octapharma.com/news/our-employees/2017/separating-plasma-proteins https://www.octapharma.com/news/patient-stories/2016/the-tainted-blood-scandal-was-hugely-tragic-but-very-instructive- https://www.octapharma.com/products/product-overview/octanine https://www.octapharma.com/news/our-employees/2017/maintaining-the-cold-chain https://www.octapharma.com/about-us/our-locations https://www.octapharma.com/news/patient-stories/2016/i-never-let-haemophilia-dictate-how-i-live-my-life https://www.octapharma.com/products/product-overview/octaplasLG https://www.octapharma.com/news/our-employees/2017/around-the-clock-production https://www.octapharma.com/news/our-employees/2017/documenting-the-complete-history-of-every-production-batch https://www.octapharma.com/products/product-overview/octaplex https://www.octapharma.com/news/patient-stories/2016/i-want-to-be-a-superhero https://www.octapharma.com/news/patient-stories/2016/haemophilia-is-just-a-part-of-who-my-sons-are https://www.octapharma.com/products/product-overview/panzyga https://www.octapharma.com/news/our-employees/2017/performing-analytical-methods https://www.octapharma.com/products/product-overview/rhesonativ https://www.octapharma.com/news/our-employees/2017/detecting-viruses-early https://www.octapharma.com/news/our-employees/2017/ensuring-safety-and-suitability-of-donors https://www.octapharma.com/products/product-overview/wilate https://www.octapharma.com/australia https://www.octapharma.com/news/our-employees/2017/controlling-the-plasma https://www.octapharma.com/azerbaijan https://www.octapharma.com/news/our-employees/2017/research-that-helps-people https://www.octapharma.com/belarus https://www.octapharma.com/belgium https://www.octapharma.com/china https://www.octapharma.com/czech-republic https://www.octapharma.com/denmark https://www.octapharma.com/jordan https://www.octapharma.com/kazakhstan https://www.octapharma.com/poland https://www.octapharma.com/saudi-arabia https://www.octapharma.com/serbia https://www.octapharma.com/singapore https://www.octapharma.com/slovakia https://www.octapharma.com/south-africa https://www.octapharma.com/brazil https://www.octapharma.com/portugal https://www.octapharma.com/spain https://www.octapharma.com/ukraine